The company’s first product Efemia was launched on the Swedish market on the 1st of October

First nine months (January – September 2018)

  • The company’s sales amounted to 0 (0) KSEK. 
  • Other operating income amounted to 17 (153) KSEK. 
  • Capitalised development expenses amounted to 428 (522) KSEK. 
  • Operating costs amounted to 7 048 (5 886) KSEK. 
  • Result before and after tax amounted to -6 604 (-5 211) KSEK. 
  • Result per share amounted to -0,68 (-0,61) SEK. 
  • Cash and cash equivalents at the end of the period amounted to 16 297 KSEK. 

Third quarter (July – September 2018) 

  • Other operating income amounted to 17 (153) KSEK. 
  • Capitalised development expenses amounted to 67 (170) KSEK. 
  • Operating costs amounted to 2 537 (2 076) KSEK. 
  • Result before and after tax amounted to -2 453 (-1 753) KSEK. 
  • Result per share amounted to -0,24 (-0,19) SEK.

CEO Karin Bryder summarises the quarter 

During the third quarter of 2018 we received the CE mark approval for Efemia continence support, our first product. We also focused on the preparations for the market launch of the product that was initiated after the end of the period. Efemia has been developed for several years, and we are happy to now be able to offer a unique solution that can change the everyday life for a large number of women. With the market launch, Invent Medic is starting a new  chapter with the Efemia launch in the Nordics and then the rest of Europe followed by the USA as the main priority. At present, the product is available for businesses and individuals through Arcamea’s online store, and we are also in discussions with potential distributors and pharmacies to make the product visible to even more women and possible to purchase through retail stores.

Download: Release